Excellence Forums

Leaders in the field sharing authoritative insights and institutional best practices.
In this Q&A, Page B. Pennell, MD, answers our questions about her study, which indicated that changes in antiepileptic drug dose appear to be more common among pregnant women compared with nonpregnant women.
Elysa Widjaja, MD, MPH, answered our questions about her new study, which suggested that more than 50% of children who undergo MRI-guided laser interstitial thermal therapy have seizure freedom at 1 year. These findings were presented at the American Epilepsy Society virtual meeting, AES2020.
He discusses his research on cenobamate as adjunctive therapy for adults with uncontrolled focal seizures, how the results of this research aided in cenobamate's approval by the Food and Drug Administration, and more.
In this podcast, Chrystal M. Reed, MD, PhD, discusses her team’s research on the association between interictal epileptiform discharges and transient cognitive impairments in patients with chronic epilepsy.
In this commentary, Joe McSherry, MD, PhD, discusses the safety and effectiveness of cannabinoids as alternative treatment options, despite widespread controversy.
Recent research has deepened our understanding and management of pediatric epilepsy emergencies. Renée Shellhaas, MD, MS, answers our questions.
She outlines the challenges associated with diagnosing psychogenic nonepileptic seizures (PNES), how neurologists and other providers can overcome these challenges, and more.
The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy project aims to better understand epilepsy and, therefore, to develop epilepsy-preventive therapies. Project Director of EpiBioS4Rx Jerome Engel, Jr., MD, PhD, answers our questions about this project.
In this special installment of Podcasts360, Andrew Blum, MD, PhD, and Wael Asaad, MD, PhD, discuss their case series on responsive neurostimulation, why they chose responsive neurostimulation for each patient, and how the technology has evolved over the years.